Skip to main content

Table 1 Some drugs are already in clinical trials.

From: Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment

Treatment

Phase

Tumor types

Efficacy

ClinicalTrials.gov Identifier

Talazoparib

III

Advanced and/or metastatic breast cancer with BRCA mutation

PFS: 8.6 months

NCT01945775

Niraparib + Pembrolizumab

I/II

Ovarian Cancer/TNBC

ORR: 15.1%/18.2%

NCT02657889

Niraparib + Pembrolizumab

II

NSCLC

ORR: 56.3%

NCT03308942

Pamiparib + Tislelizumab

I/Ib

TNBC with either known germline or somatic BRCA1/2 mutations or with documented HRD

ORR: 47.4%

PFS: 8.4 months

NCT02660034

Daratumumab

II

Follicular Lymphoma

ORR: 12.5%

PFS: 3.3 months

NCT02413489

Isatuximab + Cemiplimab

I/II

Metastatic castration-resistant prostate cancer (mCRPC) or advanced non-small cell lung cancer (NSCLC)

lack of efficacy

NCT03367819

OT-82

I

Relapsed or Refractory Lymphoma

No results

NCT03921879

ATG−019

I

Solid Tumor, Non-Hodgkin’s Lymphoma

No results

NCT04281420

KPT−9274

I

Acute Myeloid Leukemia

No results

NCT04914845

  1. PARP inhibitors: Talazoparib, Niraparib, Pamiparib; PD-L1 antibody: Pembrolizumab; PD-1 antibody: Tislelizumab, Cemiplimab; CD38 monoclonal antibody: Isatuximab; NAMPT inhibitor: OT-82, ATG-019,KPT-9274
  2. TNBC Triple-negative breast cancer, NSCLC non-small cell lung cancer, HRD Homologous recombination defect, PFS progression-free survival, ORR objective response rate